B
Bull
Bull · 25%ROIV
$12.69
Scenario price
$34.710
-2.652 (-7.64%)At close
Loading chart…
- High
- 37.130
- Open
- 37.010
- VWAP
- 35.51
- Vol
- 8.76M
- Mkt Cap
- 7.81B
- Low
- 34.685
- Amount
- 311.23M
- EV/EBITDA, TTM
- -0.25
Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
AI analysis of Roivant Sciences Ltd (ROIV)
buyRoivant Sciences Ltd is a good buy right now due to its recent FDA approval of LISRAYA, which is expected to significantly enhance revenue potential. The current price is $34.71, while analysts have set price targets as high as $50, suggesting a potential upside of over 44%. Additionally, the stock's RSI is at 31.36, indicating it may be oversold, which could present a buying opportunity. However, the company has reported significant net losses, with a net income of -$265.89 million in Q3 2026, which remains a key risk.
Valuation Metrics
The current forward P/E ratio for Roivant Sciences Ltd (ROIV) is 0.00, compared to its 5-year average forward P/E of -8.02.
Alphio AI Price Scenarios for ROIV
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding ROIV
Events Timeline
News
9.008-27NASDAQ.COMFDA Approves LISRAYA for Dermatomyositis Treatment
8.508-27NewsfilterFDA Approves LISRAYA for Dermatomyositis Treatment
- 2.008-26Newsfilter
Brepocitinib Shows Significant Efficacy in Dermatomyositis Treatment
8.508-21stocktwitsArbutus Biopharma Announces $230 Million Share Repurchase Plan
9.508-06seekingalphaRoivant Sciences Q1 Earnings Report Analysis
ROIV FAQ — answered by Alphio AI
Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Roivant Sciences Ltd is a good buy right now due to its recent FDA approval of LISRAYA, which is expected to significantly enhance revenue potential. The current price is $34.71, while analysts have set price targets as high as $50, suggesting a potential upside of over 44%. Additionally, the stock's RSI is at 31.36, indicating it may be oversold, which could present a buying opportunity. However, the company has reported significant net losses, with a net income of -$265.89 million in Q3 2026, which remains a key risk.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。